中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
8期
1064-1065
,共2页
替罗非班%经皮冠状动脉介入术%白细胞介素%C反应蛋白
替囉非班%經皮冠狀動脈介入術%白細胞介素%C反應蛋白
체라비반%경피관상동맥개입술%백세포개소%C반응단백
Tirofiban%Percutaneous coronary intervention%Interleukin%C reactive protein
目的 研究替罗非班对经皮冠状动脉介入(PCI)患者白细胞介素(IL)及C反应蛋白(CRP)水平的影响.方法 选取行PCI术治疗的78例急性心肌梗死患者为研究对象,将其完全随机分为常规治疗的对照组(39例)和常规治疗基础上加用替罗非班治疗的观察组(39例),比较2组患者治疗总有效率、PCI术前以及术后24、72 h血清IL-6、IL-8、IL-I0及CRP水平.结果 观察组的治疗总有效率高于对照组[97.4％(38/39)比89.7％(35/39)],差异有统计学意义(P＜0.05).观察组和对照组术后24、72 h血清CRP、IL-6、IL-8、IL-10水平均明显低于术前[对照组:(10.4±3.1)、(7.6±2.9) mg/L比(13.5±3.7) mg/L,(55±4)、(40 ±4) mg/L比(70±5)mg/L,(67±5)、(48±3)mg/L/比(90±7)mg/L,(8.8±1.3)、(8.0±1.3) mg/L比(9.8±1.5)mg/L；观察组:(7.3±2.8)、(4.7±2.3)mg/L比(13.5±3.7) mg/L,(42±4)、(29±3)mg/L比(69±5) mg/L,(55±5)、(40±3)mg/L比(90±7)mg/L,(7.6±1.3)、(6.8±1.2)mg/L比(9.9±1.5) mg/L],差异均有统计学意义(均P＜0.05)；术后24、72 h,观察组血清IL-6、IL-8、IL-10、CRP水平均明显低于对照组,差异均有统计学意义(均P ＜0.05).结论 替罗非班可明显减低PCI术患者IL及CRP水平,对PCI术患者具有保护作用.
目的 研究替囉非班對經皮冠狀動脈介入(PCI)患者白細胞介素(IL)及C反應蛋白(CRP)水平的影響.方法 選取行PCI術治療的78例急性心肌梗死患者為研究對象,將其完全隨機分為常規治療的對照組(39例)和常規治療基礎上加用替囉非班治療的觀察組(39例),比較2組患者治療總有效率、PCI術前以及術後24、72 h血清IL-6、IL-8、IL-I0及CRP水平.結果 觀察組的治療總有效率高于對照組[97.4％(38/39)比89.7％(35/39)],差異有統計學意義(P＜0.05).觀察組和對照組術後24、72 h血清CRP、IL-6、IL-8、IL-10水平均明顯低于術前[對照組:(10.4±3.1)、(7.6±2.9) mg/L比(13.5±3.7) mg/L,(55±4)、(40 ±4) mg/L比(70±5)mg/L,(67±5)、(48±3)mg/L/比(90±7)mg/L,(8.8±1.3)、(8.0±1.3) mg/L比(9.8±1.5)mg/L；觀察組:(7.3±2.8)、(4.7±2.3)mg/L比(13.5±3.7) mg/L,(42±4)、(29±3)mg/L比(69±5) mg/L,(55±5)、(40±3)mg/L比(90±7)mg/L,(7.6±1.3)、(6.8±1.2)mg/L比(9.9±1.5) mg/L],差異均有統計學意義(均P＜0.05)；術後24、72 h,觀察組血清IL-6、IL-8、IL-10、CRP水平均明顯低于對照組,差異均有統計學意義(均P ＜0.05).結論 替囉非班可明顯減低PCI術患者IL及CRP水平,對PCI術患者具有保護作用.
목적 연구체라비반대경피관상동맥개입(PCI)환자백세포개소(IL)급C반응단백(CRP)수평적영향.방법 선취행PCI술치료적78례급성심기경사환자위연구대상,장기완전수궤분위상규치료적대조조(39례)화상규치료기출상가용체라비반치료적관찰조(39례),비교2조환자치료총유효솔、PCI술전이급술후24、72 h혈청IL-6、IL-8、IL-I0급CRP수평.결과 관찰조적치료총유효솔고우대조조[97.4％(38/39)비89.7％(35/39)],차이유통계학의의(P＜0.05).관찰조화대조조술후24、72 h혈청CRP、IL-6、IL-8、IL-10수평균명현저우술전[대조조:(10.4±3.1)、(7.6±2.9) mg/L비(13.5±3.7) mg/L,(55±4)、(40 ±4) mg/L비(70±5)mg/L,(67±5)、(48±3)mg/L/비(90±7)mg/L,(8.8±1.3)、(8.0±1.3) mg/L비(9.8±1.5)mg/L；관찰조:(7.3±2.8)、(4.7±2.3)mg/L비(13.5±3.7) mg/L,(42±4)、(29±3)mg/L비(69±5) mg/L,(55±5)、(40±3)mg/L비(90±7)mg/L,(7.6±1.3)、(6.8±1.2)mg/L비(9.9±1.5) mg/L],차이균유통계학의의(균P＜0.05)；술후24、72 h,관찰조혈청IL-6、IL-8、IL-10、CRP수평균명현저우대조조,차이균유통계학의의(균P ＜0.05).결론 체라비반가명현감저PCI술환자IL급CRP수평,대PCI술환자구유보호작용.
Objective To study the effects of tirofiban on interleukin(IL) and C reactive protein (CRP) in patients treated with percutaneous coronary intervention (PCI).Methods All 78 patients with PCI were randomly divided into the observation group (n =39) and control group (n =39).The patients in observation group were treated with tirofiban besides conventional therapy; the patients in control group were treated only with conventional therapy.Plasma levels of IL-6,IL-8,IL-10 and CRP were measured and compared before treatment and 24,72 h after treatment.Results The total effective rate in observation group was higher than that in control group[97.4％ (38/39) vs 89.7％ (35/39),P ＜ 0.05].After treatment for 24,72 h,the plasma levels of CRP,IL-6,IL-8 and IL-10 were lower than those before treatment in observation group and control group[control group:(10.4 ± 3.1),(7.6 ±2.9)mg/L vs (13.5 ±3.7)mg/L,(55 ±4),(40 ±4)mg/L vs (70 ±5)mg/L,(67 ±5),(48 ±3)mg/L vs (90 ± 7) mg/L,(8.8 ± 1.3),(8.0 ± 1.3) mg/L vs (9.8 ± 1.5) mg/L; observation group:(7.3 ± 2.8),(4.7 ±2.3)mg/L vs(13.5 ±3.7)mg/L,(42 ±4),(29±3)mg/L vs (69 ±5)mg/L,(55 ±5),(40 ±3)mg/L vs (90 ± 7) mg/L,(7.6 ± 1.3),(6.8 ± 1.2) mg/L vs (9.9 ± 1.5) mg/L],and the plasma levels of CRP,IL-6,IL-8 and IL-10 in observation group were lower than those in control group,and the difference was statistically significant (P ＜ 0.05).Conclusion Tirofiban can significandy reduce the levels of interleukin and CRP levels of patients with PCI.
